Scarica l'app Stockscreener
18.50
2.43%
-0.46
Dopo l'orario di chiusura:
18.54
0.04
+0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$18.96
Aprire:
$18.75
Volume 24 ore:
837.91K
Relative Volume:
0.55
Capitalizzazione di mercato:
$1.41B
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-8.2589
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
-2.12%
1M Prestazione:
-22.01%
6M Prestazione:
+315.73%
1 anno Prestazione:
+193.19%
Intervallo 1D:
$17.98
$19.16
Intervallo di 1 settimana:
$17.98
$20.29
Portata 52W:
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
18.50 | 1.45B | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Monte Rosa Therapeutics, Inc. Announces Executive Changes, Effective April 3, 2026 - marketscreener.com
Smart Money: How sensitive is Monte Rosa Therapeutics Inc to inflationEarnings Growth Report & Technical Buy Zone Confirmations - baoquankhu1.vn
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher - Investing.com
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains - Yahoo Finance
Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Spikes: Is Monte Rosa Therapeutics Inc stock a good pick for beginnersBuy Signal & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Drop in Short Interest - MarketBeat
Winners Losers: Can Monte Rosa Therapeutics Inc ride the EV waveWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Monte Rosa Therapeutics Inc. subject to activist investor interestPortfolio Profit Report & Daily Entry Point Trade Alerts - mfd.ru
Promising Small Cap Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9%What's Next? - MarketBeat
Aug Volume: What are Monte Rosa Therapeutics Incs earnings expectationsIPO Watch & Detailed Earnings Play Strategies - baoquankhu1.vn
Aug Gainers: Is Monte Rosa Therapeutics Inc stock a hidden gemJuly 2025 Earnings & Weekly High Potential Stock Alerts - baoquankhu1.vn
51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Biotech Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Monte Rosa Therapeutics announces pricing of $300M stock offering - MSN
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7% - MarketBeat
Goodwin Guides Monte Rosa Therapeutics In Pricing Of $300 Million Underwritten Public Offering - Mondaq
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise - Sahm
Monte Rosa Therapeutics (GLUE) Price Target Increased by 30.77% to 28.49 - Nasdaq
Aug Highlights: Does Monte Rosa Therapeutics Inc stock trade at a discount to peersWeekly Trend Report & High Return Stock Watch Alerts - Bộ Nội Vụ
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum - Yahoo Finance
How institutional buying supports Monte Rosa Therapeutics Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - Улправда
Latham & Watkins Advises on Monte Rosa Therapeutics’ US$300 Million Underwritten Public Offering - Latham & Watkins LLP
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Monte Rosa Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView — Track All Markets
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares - Nasdaq
Why Monte Rosa Therapeutics Inc. stock is considered a top pickWeekly Investment Recap & Risk Managed Investment Strategies - ulpravda.ru
Monte Rosa Therapeutics prices $300 million public offering By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Monte Rosa Therapeutics prices $300 million public offering - Investing.com
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Yahoo Finance
Biotech Monte Rosa is selling $300M in new shares to investors - Stock Titan
Monte Rosa Therapeutics announces pricing of $300 million underwritten public offering at $24.00 per share - marketscreener.com
Can Monte Rosa Therapeutics Inc. stock beat analyst upgradesJuly 2025 Highlights & AI Forecasted Stock Moves - ulpravda.ru
GLUE Stock: Guggenheim Maintains Buy Rating, Raises Price Target - GuruFocus
Will Monte Rosa Therapeutics Inc. stock attract more institutional investorsWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - Улправда
Is Monte Rosa Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Snapshot & Accurate Buy Signal Notifications - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Why Monte Rosa Therapeutics Inc. stock is a must watch in 2025Weekly Profit Summary & Community Trade Idea Sharing - ulpravda.ru
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
GLUE Stock Receives Analyst Rating Update with Raised Price Targ - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $34.00 Price Target at Guggenheim - MarketBeat
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
Monte Rosa Therapeutics Reaches Analyst Target Price - Nasdaq
Monte Rosa Therapeutics dips after $200 mln equity offering launched - TradingView — Track All Markets
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Strong-Buy - MarketBeat
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):